.png){kind=icon}
.png){kind=icon}
Return
Precision oncology needs precision trial design: lessons from FGFR2-rearranged cholangiocarcinoma
.png){kind=icon}
PRE
AI
F
L
DOI：10.1038/s41571-026-01194-3.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
The phase III FIGHT-302 trial demonstrated that the FGFR inhibitor pemigatinib improves progression-free survival and response rates versus first-line chemotherapy in patients with advanced-stage FGFR2-rearranged cholangiocarcinoma. However, the trial accrued slowly and closed early after chemoimmunotherapy became the new standard of care. FIGHT-302, alongside two similarly terminated trials, highlights the need for innovative trial designs and flexible regulatory frameworks to evaluate therapies in rare, biomarker-defined populations.
Journal
IF:
82.2
Papers:
2.3K
Citations:
3.3W
Organization
Cited Papers